Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk | Zendy

Bernard Zinman | Zendy; Silvio E. Inzucchi | Zendy; John M. Lachin | Zendy; Christoph Wanner | Zendy; David Fitchett | Zendy; Sven Köhler | Zendy; Michaela Mattheus | Zendy; Hans J. Woerle | Zendy; Uli C. Broedl | Zendy; Odd Erik Johansen | Zendy; Gregory W. Albers | Zendy; HansChristoph Diener | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Author(s) -

Bernard Zinman,

Silvio E. Inzucchi,

John M. Lachin,

Christoph Wanner,

David Fitchett,

Sven Köhler,

Michaela Mattheus,

Hans J. Woerle,

Uli C. Broedl,

Odd Erik Johansen,

Gregory W. Albers,

HansChristoph Diener

Publication year - 2017

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.015756

Subject(s) - empagliflozin , medicine , hazard ratio , placebo , stroke (engine) , diabetes mellitus , type 2 diabetes mellitus , type 2 diabetes , confidence interval , myocardial infarction , cardiology , surgery , endocrinology , mechanical engineering , alternative medicine , pathology , engineering

In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse cardiovascular events, driven by a reduction in cardiovascular mortality, with no significant difference between empagliflozin and placebo in risk of myocardial infarction or stroke. In a modified intent-to-treat analysis, the hazard ratio for stroke was 1.18 (95% confidence interval, 0.89-1.56; P =0.26). We further investigated cerebrovascular events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research